Number of participants withdrawing due to adverse events (AE) · scalp psoriasis
Steroid probably leads to lower number of participants withdrawing due to adverse events (AE) compared with vitamin D (moderate certainty).
1 finding from 1 review
Number of participants achieving 'response' by PGA · scalp psoriasis
Steroid probably leads to higher number of participants achieving 'response' by PGA compared with vitamin D (moderate certainty).
1 finding from 1 review
Cramp intensity (on 3‐point scale; 1 = mild; 2 = moderate; 3 = severe) · patients with muscle cramps
1 finding from 1 review
Major adverse events · patients with muscle cramps
1 finding from 1 review
Minor adverse events · patients with muscle cramps
1 finding from 1 review
Number of cramps over 2 weeks · patients with muscle cramps
1 finding from 1 review
Cramp intensity (on 3‐point scale; 1 = mild; 2 = moderate; 3 = severe) · patients with muscle cramps
1 finding from 1 review
Major adverse events · patients with muscle cramps
1 finding from 1 review
Minor adverse events · patients with muscle cramps
1 finding from 1 review
Number of cramps over 2 weeks · patients with muscle cramps
1 finding from 1 review
Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl... · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Progression to geographic atrophy · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to geographic atrophy compared with placebo (low certainty).
1 finding from 1 review
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with AMD
Lutein with or without zeaxanthin showed no clear difference in progression to visual loss (loss of 3 or more lines on logMAR chart) compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with AMD
1 finding from 1 review